Navigation Links
TPI to Host Fiscal Year 2013 Earnings Conference Call on Friday, September 27th, 2013 at 9 a.m. ET
Date:9/19/2013

CHENGDU, China, Sept. 19, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the fiscal year 2013 ending June 30, 2013 to be held at 9:00 a.m. ET on Friday, September 27th, 2013.

Interested parties may access the call by dialing:

TOLL-FREE    1-877-941-2068
TOLL/INTERNATIONAL    1-480-629-9712

The conference ID is 4640745. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling:

TOLL-FREE   1-877-870-5176
TOLL/INTERNATIONAL   1-858-384-5517

From:  09/27/13 @ 12:00 pm Eastern Time
To:    10/11/13 @ 11:59 pm Eastern Time
Replay Pin Number:  4640745

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=106103

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit:  http://www.tianyinpharma.com

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia

Tel:     +86-28-8551-6696 (Chengdu, China)

            +86-134-3655-0011 (China)

Address:

Tianyin Pharmaceutical

23rd Floor, Unionsun Yangkuo Plaza     

No. 2, Block 3, South Renmin Road

Chengdu, 610041

China


'/>"/>
SOURCE TPI
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
2. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
3. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Fourth Quarter
4. Tekni-Plex, Inc. To Hold Teleconference To Discuss Financial Results For Fiscal Year 2013 On September 12, 2013
5. Unilife Corporation To Announce Financial Results For Fiscal Year 2013 Fourth Quarter And Year End On Tuesday, September 10, 2013
6. Accuray Announces Results for Fourth Quarter and Fiscal Year 2013
7. China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2014 First Quarter Earnings Results and Schedules Conference Call for August 19, 2013
8. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue and Earnings
9. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
10. CareFusion Reports Fourth Quarter And Fiscal 2013 Results
11. Cyberonics To Report Fiscal Year 2014 First Quarter Results And Host Webcast And Conference Call On August 22, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):